|
|
www.news.medizin-2000.de
|
Home |
Facheingang
|
Suche
| Nutzung
| Impressum|
Kontakt
|
Die werbe-freie
online Enzyklopädie Wikipedia
zum
Thema Arthrose
hier
Naturheilkunde: alternative Rheuma-Therapie.
Die
rheumatoide Arthritis gehört im fortgeschrittenen
Lebensalter zu den eher häufigen und sehr
schmerzhaften Erkrankungen. Durch die chronische
Entzündung der Gelenke kommt es im Verlauf
der Krankheit zu schweren deformierenden
Gelenkveränderungen und sogar zu einer erhöhten
Gesamtsterblichkeit.
Jetzt haben Forscher in einer im renommierten
Fachblatt Anals of Internal Medicine
veröffentlichten Studie nachweisen können,
dass das traditionelle chinesische Heilmittel
"lei gong teng" oder auf Englisch
"thunder god vine") eine bessere
Heilwirkung entfaltet als das Standard-Medikament
Sulfasalazine.
Der Pflanzenwirkstoff
wird aus den
Wurzeln
des medizinischen Weins
Tripterygium wilfordii
Hook F (TwHF) hergestellt. Von den rund 380
aus der Wurzel isolierten Wirkstoffen sind
95% Terpenoide. Die drei häufigsten
sind Triptolide, Tripdiolide
und Triptonide . Diese sind für die immunsuppressive
Wirkung des Medikaments verantwortlich.
Da die Zahl der Patienten die die Studie beendeten
relativ klein war, kann diese Untersuchung
nur die Annahme stützen, dass das chinesische
Arzneimittel wahrscheinlich bei Arthritis
eine gute Wirkung entfaltet. Für den endgültigen
Beweis dieser Wirksamkeit - und die
gute Verträglichkeit - sind aber unbedingt
noch einige größere zusätzliche Studien erforderlich.
18 August 2009 | Volume 151 Issue 4 | Pages 229-240
Comparison
of Tripterygium wilfordii Hook F Versus
Sulfasalazine in
the Treatment of Rheumatoid Arthritis
A Randomized Trial
Background: Extracts of the medicinal plant Tripterygium wilfordii Hook F (TwHF) have been used in China for centuries to treat a spectrum of inflammatory diseases.
Objective: To compare the benefits and side effects of TwHF extract with those of sulfasalazine for the treatment of active rheumatoid arthritis.
Design: Randomized, controlled trial. A computer-generated code with random, permuted blocks was used to assign treatment.
Setting: 2 U.S. academic centers (National Institutes of Health, Bethesda, Maryland, and University of Texas, Dallas, Texas) and 9 rheumatology subspecialty clinics (in Dallas and Austin, Texas; Tampa and Fort Lauderdale, Florida; Arlington, Virginia; Duncanville, Pennsylvania; Wheaton and Greenbelt, Maryland; and Lansing, Michigan).
Patients: 121 patients with active rheumatoid arthritis and 6 or more painful and swollen joints.
Intervention: TwHF extract, 60 mg 3 times daily, or sulfasalazine, 1 g twice daily. Patients could continue stable doses of oral prednisone or nonsteroidal anti-inflammatory drugs but had to stop taking disease-modifying antirheumatic drugs at least 28 days before randomization.
Measurements: The primary outcome was the rate of achievement of 20% improvement in the American College of Rheumatology criteria (ACR 20) at 24 weeks. Secondary end points were safety; radiographic scores of joint damage; and serum levels of interleukin-6, cholesterol, cortisol, and adrenocorticotropic hormone.
Results: Outcome data were available for only 62 patients at 24 weeks. In a mixed-model analysis that imputed data for patients who dropped out, 65.0% (95% CI, 51.6% to 76.9%) of the TwHF group and 32.8% (CI, 21.3% to 46.0%) of the sulfasalazine group met the ACR 20 response criteria (P = 0.001). Patients receiving TwHF also had significantly higher response rates for ACR 50 and ACR 70 in mixed-model analyses. Analyses of only completers showed similar significant differences between the treatment groups. Significant improvement was demonstrated in all individual components of the ACR response, including the Health Assessment Questionnaire disability score. Interleukin-6 levels rapidly and significantly decreased in the TwHF group. Although not statistically significant, radiographic progression was lower in the TwHF group. The frequency of adverse events was similar in both groups.
Limitations: Only 62% and 41% of patients continued receiving TwHF extract and sulfasalazine, respectively, during the 24 weeks of the study. Long-term outcome data were not collected on participants who discontinued treatment.
Conclusion: In patients who continued treatment for 24 weeks and could also use stable oral prednisone and nonsteroidal anti-inflammatory drugs, attainment of the ACR 20 response criteria was significantly greater with TwHF extract than with sulfasalazine.
Primary Funding Source: National Institute of Arthritis and Musculoskeletal and Skin Diseases.
 ÄRZTE
FÜR TIERE e. V. verfolgt zwei grundsätzliche Ziele:
den politischen Tierschutz und die Förderung tiergestützter Therapieformen. mehr |
|
|